effect of betahistine and dimenhydrinate in benign paroxysmal positional vertigo

Comparison Effect of betahistine and dimenhydrinate with Epley maneuver to improve symptoms in patients with benign paroxysmal positional vertigo

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201506231138N20

Enrollment

120

Registered

2016-01-01

Start date

2015-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign paroxysmal vertigo. benign paroxysmal positional vertigo

Interventions

Intervention 1: Intervention Group : Epley maneuver with dimenhydrinate. Intervention 2: Intervention group : Epley maneuver with betahistine. Intervention 3: Control Group : Epley maneuver with plac

Treatment - Drugs

Placebo

Intervention Group : Epley maneuver with dimenhydrinate

Intervention group : Epley maneuver with betahistine

Control Group : Epley maneuver with placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Unknown BPPV; Successful epley maneuver; Patients who don't receive any medication. Exclusion criteria: The inner ear disease; The inner or middle ear surgery; Migraine and headache during the study period; Using Psycho-neurological drugs during the study; The involvement more than one of a semi-circular canal; Re-Appearance of nystagmus after epley maneuver.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lightheadedness. Timepoint: Before starting the medication, and 1 week after starting drug. Method of measurement: Physical examination.;Diagnosis of BPPV. Timepoint: at the first study, One week after epley maneuver. Method of measurement: hallpike dix test.;Feeling of floating. Timepoint: Before starting the medication, and 1 week after starting drug. Method of measurement: Physical examination.;Dizziness. Timepoint: Before starting the medication, and 1 week after starting drug. Method of measurement: Physical examination.;Ear fullness. Timepoint: Before starting the medication, and 1 week after starting drug. Method of measurement: Physical examination.;Weakness. Timepoint: Before starting the medication, and 1 week after starting drug. Method of measurement: Physical examination.	—

Measure

Time frame

Lightheadedness. Timepoint: Before starting the medication, and 1 week after starting drug. Method of measurement: Physical examination.;Diagnosis of BPPV. Timepoint: at the first study, One week after epley maneuver. Method of measurement: hallpike dix test.;Feeling of floating. Timepoint: Before starting the medication, and 1 week after starting drug. Method of measurement: Physical examination.;Dizziness. Timepoint: Before starting the medication, and 1 week after starting drug. Method of measurement: Physical examination.;Ear fullness. Timepoint: Before starting the medication, and 1 week after starting drug. Method of measurement: Physical examination.;Weakness. Timepoint: Before starting the medication, and 1 week after starting drug. Method of measurement: Physical examination.

—

Secondary

Measure	Time frame
Quality of life. Timepoint: Before and after intervention. Method of measurement: The questionnaire Dizziness Handicap Inventory (DHI) and Berg balance scale (modified).;Daily activities. Timepoint: Before and after intervention. Method of measurement: The questionnaire Dizziness Handicap Inventory (DHI) and Berg balance scale (modified).;Disease severity. Timepoint: Before and after intervention. Method of measurement: The questionnaire Dizziness Handicap Inventory (DHI) and Berg balance scale (modified).;Emotional state. Timepoint: Before and after intervention. Method of measurement: The questionnaire Dizziness Handicap Inventory (DHI) and Berg balance scale (modified).	—

Measure

Time frame

Quality of life. Timepoint: Before and after intervention. Method of measurement: The questionnaire Dizziness Handicap Inventory (DHI) and Berg balance scale (modified).;Daily activities. Timepoint: Before and after intervention. Method of measurement: The questionnaire Dizziness Handicap Inventory (DHI) and Berg balance scale (modified).;Disease severity. Timepoint: Before and after intervention. Method of measurement: The questionnaire Dizziness Handicap Inventory (DHI) and Berg balance scale (modified).;Emotional state. Timepoint: Before and after intervention. Method of measurement: The questionnaire Dizziness Handicap Inventory (DHI) and Berg balance scale (modified).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Hooshang Gerami

Guilan University of Medical Sciences

hg_gerami@yahoo.com+98 13 3322 5242

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026